New analyses of tramiprosate data presented at CTAD

9 December 2016

Closely-held US biotech firm Alzheon has presented new analyses of previous Phase III data for tramiprosate, an investigational amyloid anti-aggregation agent and the active molecule of prodrug ALZ-801, in an oral presentation at the 9th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego.

The new results strengthen Alzheon's precision medicine approach which identifies distinct biological phenotypes in Alzheimer’s disease (AD) patients.

These phenotypes were described in the recently-published analyses of the tramiprosate Phase III data, showing that AD patients who carry two e4 alleles of apolipoprotein E gene (APOE4/4 homozygotes) respond with the largest clinical benefits.

The results show tramiprosate’s largest efficacy signals on cognition and function in APOE4/4 homozygous patients with mild AD, defined as MMSE of 22 and higher.

Alzheon also presented a poster on the Phase I clinical studies and bridging data for ALZ-801, an optimized prodrug of tramiprosate, that support the pivotal clinical program planned to begin in 2017, which will evaluate ALZ-801 as a potential disease-modifying treatment for APOE4/4 homozygous patients at the mild stage of Alzheimer’s disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK